Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors.
Cid-Silva, Purificación; Margusino-Framinan, Luis; Balboa Barreiro, Vanesa; Martin-Herranz, Isabel; Castro-Iglesias, Angeles; Pernas-Souto, Berta; Llibre, Josep M.; Poveda, Eva
HIV-1 subtype B (54.4%) and subtype F (27.2%) are the most prevalent variants in patients who started antiretroviral therapy including an integrase inhibitor in the last 2 years in Northwest Spain. Virological response rates to antiretroviral therapy based on integrase inhibitor were significantly lower among F subtypes compared with B subtypes at weeks 12 (25.0% vs. 75.0%) and 24 (59.1% vs. 95.0%). Subtype F was independently associated with virological response at 24 weeks [odds ratio 11.8 (95% confidence interval 1.1-119.9); P=0.037].